Suffern, NY, United States of America

Scott Ellis Lomberk

This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Pfizer Corporation. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott Ellis Lomberk. Retrieved from https://idiyas.com/inventor/scott-ellis-lomberk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 13.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Scott Ellis Lomberk - Innovative Inventor from Suffern, NY

Introduction: Scott Ellis Lomberk is a talented inventor hailing from Suffern, NY, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Scott Ellis Lomberk holds several patents in various technological domains, showcasing his versatility and creativity in inventing new solutions to modern challenges.

Career Highlights: Throughout his illustrious career, Scott Ellis Lomberk has consistently pushed the boundaries of innovation, with his inventions revolutionizing industries and improving the lives of many.

Collaborations: Scott Ellis Lomberk has collaborated with leading tech companies and research institutions, leveraging his expertise to bring cutting-edge ideas to life through strategic partnerships.

Conclusion: Scott Ellis Lomberk's passion for innovation and his dedication to creating impactful inventions have solidified his reputation as a visionary inventor in the tech world.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…